Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069686 | 0.88 | L3MBTL1 (0.44) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL21651938 | 0.85 | LMNA (0.46) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL22857099 | 0.83 | LMNA (0.40) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL20148096 | 0.82 | LMNA (0.50) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL20148097 | 0.79 | OPRM1 (0.51) | LMNAKMT2AMEN1MAPK1POLB | |
| SCHEMBL164041 | 0.78 | ALDH1A1 (0.40) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL1691128 | 0.75 | SMN1; SMN2 (0.42) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL1691141 | 0.75 | CYP4F2 (0.41) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL12140578 | 0.74 | SMN1; SMN2 (0.36) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL2185965 | 0.73 | CYP4F2 (0.40) | KMT2AMEN1MAPK1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | LMNA 1968/4885KMT2A 1112/4885MEN1 653/4885 |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | LMNA 1968/4885KMT2A 1112/4885MEN1 653/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | LMNA 1968/4885KMT2A 1112/4885MEN1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.